调强放疗联合化疗治疗肝癌合并门静脉癌栓或下腔静脉癌栓的效果观察

目的探讨调强放疗联合化疗治疗肝癌合并门静脉癌栓(PVTT)或下腔静脉癌栓(IVCTT)的临床效果。方法选取2017年8月至2019年2月我院收治的93例肝癌合并PVTT/IVCTT患者,按照入院顺序分为基础组(调强放疗,43例)和联合组(调强放疗联合奥沙利铂综合治疗,50例),比较两组患者的临床疗效及相关不良反应发生率。结果联合组的治疗总有效率为54.00%,显著高于基础组的27.91%(P <0.05)。两组患者的消化道反应、放射性肝损伤、血液毒性发生率比较差异无统计学意义(P>0.05)。结论调强放疗联合化疗治疗肝癌合并PVTT/IVCTT可显著提高患者的临床疗效,且不增加相关不良反应发生风险,具有重要的临床价值和较高的治疗安全性。

Observation on the Effect of Intensity-Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Liver Cancer Complicated with Portal Vein Tumor Thrombus or Inferior Vena Cava Tumor Thrombus

Objective To explore the clinical effect of intensity-modulated radiotherapy combined with chemotherapy in the treatment of liver cancer complicated with portal vein tumor thrombus(PVTT)/inferior vena cava tumor thrombus(IVCTT). Methods 93 cases of patients with liver cancer complicated with PVTT/IVCTT admitted to our hospital from August 2017 to February 2019 were selected and divided into basic group(intensity-modulated radiotherapy, 43 cases) and combined group(intensity-modulated radiotherapy combined with oxaliplatin comprehensive therapy, 50 cases) according to the admission order. The clinical efficacy and incidence of related adverse reactions were compared between the two groups. Results The total effective rate of treatment in the combined group was 54.00%,significantly higher than 27.91% in the basic group(P <0.05). No statistical difference was found in the incidences of digestive tract reaction,radiation-induced liver injury and hematological toxicity between the two groups(P >0.05). Conclusions Intensity-modulated radiotherapy combined with chemotherapy in the treatment of liver cancer complicated with PVTT/IVCTT can significantly improve the clinical efficacy of patients without increasing the risk of related adverse reactions, and has important clinical value and higher treatment safety.